Core Viewpoint - The long-term follow-up results of the CAR-T cell product Zevor-cel (CT053) for treating relapsed/refractory multiple myeloma were presented at the 22nd International Myeloma Society Annual Meeting [1] Group 1: Product Information - Zevor-cel is an autologous CAR-T cell product targeting BCMA, specifically designed for the treatment of multiple myeloma (MM) [1] - The product received approval from the National Medical Products Administration on February 23, 2024, for adult patients with relapsed or refractory multiple myeloma who have progressed after at least three lines of treatment [1] - Zevor-cel was granted Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designation by the FDA in 2019 [1] Group 2: Clinical Trial Updates - The updated results of the Phase I clinical trial were presented under the title "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" at the IMS annual meeting on September 17, 2025 [1]
科济药业-B(02171)于2025年第22届IMS年会上呈列的赛恺泽?的研究成果更新